Monthly Archives: October 2013

My personal research narrative

I was recently asked by a number of people that I have met how I got started at the MS Society. Many were surprised to hear that I used to do MS research with all that you think of, the white lab coat, closed toe shoes and the ever important gloves.

My journey to the MS Society of Canada begins with the cell. The basic unit of all living organisms, the cell is an important and powerful thing. Cells make up tissues, and tissues comprise organs. Cells enable life, but to do so they need to perform very specific functions. While a student at Western University in London, I became interested in how cells behave. More specifically, I wanted to know how cells talk to one another, which they need to do in order to function and grow. In pursuit of my interests, I found myself wanting to be a cell expert. I knew that to become a cell expert, I had to continue my studies. Following completion of my undergraduate degree, I applied to a PhD program to study cell biology at the University of Ottawa. There I found myself in a lab that observed not only cells, but the cells that are most important in multiple sclerosis.

In the years that followed I spent many hours in the lab, learning about the molecular biology of MS and how it affected the Central Nervous System (CNS), comprising the brain, spinal cord and optic nerve. I learned that the body attacked the protective insulation surrounding nerve cells – called the myelin sheath – exposing the cells to damage.

The purpose of my study was to try and understand how we can get the cells that make myelin (oligodendrocytes) to communicate with one another and restore the myelin that is damaged by MS. Over and over again, in my papers and presentations, I would start every presentation saying that MS is a disease which affects the CNS, resulting in the breakdown of the myelin sheath and ultimately leading to motor and co-ordination issues in people with MS. This definition of MS was the one I knew and stuck by, the one I so deeply wanted to understand at the microscopic level. I didn’t know that I would one day see MS in a whole different light, and that the definition of MS was not as simple as I thought it was.

I was in my apartment in Ottawa one day preparing scientific reports and drawing up diagrams that explained the role of different cells in MS. I remember looking out my window and seeing a group of people participating in the MS Walk. It instantly hit me that I didn’t know a single person in the Walk, or a single person affected by MS for that matter. And there I was, studying the disease to very last detail, knowing how it affects the body but not really aware of how it affects the person.

I realized at that moment that I wanted to get more involved in the MS community, and so I reached out to the MS Society Ottawa chapter where a friendly lady named Laurel helped me get started as a volunteer. Knowing I had a science background, Laurel and the team at the Ottawa chapter had me doing everything from writing up columns about MS in chapter publications, to speaking at events in the neighbourhood. I met many great people, including those who are affected by MS.

These experiences changed the way I viewed MS. It made me witness the impact of the work I was doing, helped me put a face to my research. Most importantly, being a volunteer and working so closely with people affected by MS made me reframe my thinking of MS. The definition of MS as I saw it was not so black and white. It wasn’t just about nerve cells, inflammation and cell communication. MS is a story of uncertainty, a balancing act, a bout of fatigue and pain. MS is also motivation, a narrative of hope and courage, a test of strength and limitations. Connecting with people affected by MS gave a whole new perspective of what MS really is.

Myself as a graduate student volunteering at the Ottawa Chapter

Now as the Vice-President of Research at the MS Society, I try my best to sustain the relationships I’ve built with people in the MS community, while creating new ones. These relationships constantly inspire me, and remind me that people with MS are at the centre of what we do and are the driving force behind our cause and mission.

Are you involved with the MS Society? Share your story of how you got started in the comments section below!

Photos (top to bottom)
1. Me in the lab cutting mouse brain tissue by the micron
2. Me as a young graduate student volunteering at the MS Society Ottawa Chapter

What triggers MS?

There are many things about MS that we still do not know, but arguably the most important of these is cause. Pinning down the cause of MS has been a top priority amongst MS researchers for decades and, despite a growing body of promising evidence, the question of cause remains unresolved.

What we are learning more about are the ‘triggers of MS’, which are factors that may be contributing in one way or another to the development of disease. I already mentioned in a previous post that gender has a lot to do with MS susceptibility and severity, and recently the MS Scientific Research Foundation – an MS Society affiliated research funder – launched an extensive, multi-year study that identified different genetic and lifestyle factors which were found to be associated with MS. The study, led by Professor George Ebers who is pictured above, uncovered several important insights about MS triggers (read examples here and here).

ECTRIMS was a great platform to discuss the newest data on MS triggers. It was clear from the lectures that we are moving closer to understanding how genes, lifestyle habits, geographic location and environmental surroundings can impact one’s risk of MS. Here are some of the interesting things I heard at the conference.

Continue reading

Managing MS through physical activity

We all know without a doubt that exercise is good for us. The abundance of health benefits associated with a steady exercise regimen has made exercise an ideal complementary treatment for various diseases. But is this the case for MS?

For years, neurologists have advised people with MS to avoid physical activity as it could worsen neurological symptoms. However, new evidence suggests that exercise is, in fact, highly beneficial for people with MS and can lead to marked improvements in:

– Mobility
– Fatigue
– Depression
– Cognitive functioning

Despite the surge in scientific data reporting positive effects of exercise in MS, the fact remains that fewer than 20% of people with MS engage in adequate amounts of physical activity and the level of activity decreases over time. From speaking to many people affected by MS, I can understand why they would not be so inclined to head out to a gym or sign up for a structured exercise treatment program given the physical challenges they face on a daily basis.

According to Dr. Robert Motl, who presented on exercise in MS at ECTRIMS, there may be an effective way to boost physical activity in people with MS without having to impose a structured, supervised exercise training program.

Continue reading

Insights on inflammation – an expert view

Our immune systems are designed to fight off disease, and one way they do this is through a complex, highly controlled process known as inflammation. We know that in MS, the immune system misbehaves, and inflammation occurs not only to ward off harmful agents, but also to inflict damage on nerve tissues which comprise the brain and spinal cord.

Researchers around the world are trying to determine how inflammation drives MS disease. I met with esteemed neuroimmunologist Dr. Amit Bar-Or, who shared some valuable insight on inflammation and MS. As I mentioned in my last post, Dr. Bar-Or is both a research scientist and neurologist, which allows him to combine both clinical and laboratory expertise when trying to investigate the full impact of inflammation in MS. I wanted to know how far we’ve come in the last decade in terms of our understanding of inflammation, and what the future holds for this promising avenue of MS research. This was his response.

Continue reading

MS disease – what happens beneath the surface?

There is an ongoing debate on whether inflammation causes nervous system damage in MS, or if the damage occurs first followed by inflammation. MS Society funded researcher and neurologist Dr. Amit Bar-Or from the Montreal Neurological Institute at McGill University provided an overview of the mechanisms of inflammation during ECTRIMS. He emphasized that, regardless of what comes first – inflammation or tissue damage – inflammation is occurring in MS. But why is inflammation occurring, and what is causing it? Research is ongoing to find definitive answers for such questions.

Continue reading

Gender differences in MS

We already know that MS affects more women than men, but is that the whole story?

The MS and Gender session held late last week at ECTRIMS was an informative overview of how and why MS affects males and females differently. French researcher Dr. Vukusik, who started the session off with a lecture on the epidemiology – the study of population patterns – of MS noted that the link between MS and gender is somewhat of a paradox.

Continue reading

Interview: Dr. Erin MacMillan

Since we are on the topic of progressive MS, I thought it would be a great time share this insightful interview with Dr. Erin MacMillan who is a MS Society-funded postdoctoral fellow at the University of British Columbia. It was interesting to hear that Dr. MacMillan has a backgound in physics and we wanted to learn more about how she applies her extensive physics knowledge to detect early changes in the brain of people with MS, as well as what her research could mean for progressive MS.

Progressive MS – Where are we today?

I mentioned earlier that progressive forms of MS are still without an effective treatment, which has been recognized by the MS scientific community as a major gap that needs to be addressed.

According to Dr. Robert Fox from the Cleveland Clinic, who opened today’s session on progressive MS, there are a number of clinical trials underway showing the therapeutic potential of several treatment. Dr. Fox will be leading one of the trials, which involves evaluating the safety and tolerability of the anti-inflammatory drug ibudilast in people with progressive MS (read about the trial here). Stem cells are also being looked at for their ability to treat progressive as well as relapsing-remitting MS. Amiloride – an oral drug used to treat high blood pressure – has been shown to have nerve-protecting qualities and is now in early trials for progressive MS. Dr. Fox noted that, in the future, there should be increased focus on regenerative treatments for MS that can rebuild the tissues in the central nervous damaged from inflammation.

In an effort to address the growing need for research in progressive MS, Dr. Fox announced at ECTRIMS that several MS Societies from around the world are joining forces in a collaboration that will leverage the necessary resources to speed up the creation of progressive MS therapies. The MS Society of Canada has been a key player in this initiative since the very beginning when there were only a few of us who came together to brainstorm how we would tackle this critical priority in MS research. Today, the Progressive MS Alliance has expanded immensely, engaging the best and brightest researchers around the globe.

I, along with many of my peers here, am hopeful that the work funded by the Alliance will solve the complex puzzle of progressive MS. That is not to say that there isn’t already some excellent research happening in the field right now. Dr. Ciccarelli and her lab from the UK presented interesting data from their study on progressive MS today.

Continue reading

Interview: Dr. Yinshan Zhao

I had an opportunity to chat with Dr. Yinshan Zhao, a statistician working with the Multiple Sclerosis/MRI research group at The University of British Columbia. Dr. Zhao presented her data on the use of magnetic resonance imaging (MRI) for measuring responses to therapy here at ECTRIMS. I was happy to hear that her study, funded by the MS Society of Canada, was recently accepted by the Journal of American Statistical Association, a leading journal in statistical research. I wanted to touch base with Dr. Zhao to hear more about her work and its application in the clinic.

Continue reading

More treatment options for MS


One of the main topics being covered at ECTRIMS is MS treatment. Treatments for MS, whether disease modifying therapies (DMTs) or rehabilitation strategies, have reached an overwhelming number over the last two decades, before which there was no approved treatment available. With so many options to choose from, new questions begin to arise, such as:

  1. Which therapy or therapies should a person with a particular form of MS take?
  2. When is the best time to begin a treatment regimen?
  3. What are the long term effects of DMTs?

Researchers from around the world have come to ECTRIMS to share new data that is helping to answer some of these questions.

MS treatment – revolution or evolution?

While the management of relapsing-remitting forms of MS has been declared by some as a ‘revolution’, treatment for other, more severe types of MS remain elusive.

“There are, to date, nearly 10 treatments available for relapsing-remitting MS, but there is still no therapy for progressive MS” – says Professor Per Soelberg Sørensen, Chair of 2013 ECTRIMS during a press conference. “This would likely classify progressive MS treatment as more of an ‘evolution’ which requires further research”.

There is, however, a silver lining for people with progressive MS as well as relapsing-remitting MS – early treatment. This is a topic that received much attention over the past few days, as there is growing evidence showing that treating MS as early as possible can have a significant impact in long-term treatment response, quality of life, and disease progression in people with MS. Professor Hans-Peter Hartung from Germany noted at yesterday’s symposium that early diagnosis and treatment is key in reducing disability and maximizing quality of life. Professor Gavin Giovanni, who presented shortly after, added that initiating treatment with DMTs at the first signs of relapse has major benefits. This was demonstrated in trials involving early treatment with natalizumab (Tysabri, Biogen Idec) which led to better relapse recovery, improvements in areas such as cognition, vision and fatigue, and a stable EDSS score (an important measure of disability).

There have been several other presentations discussing the positive outcomes of managing MS in the earlier phase of disease, labeling this period as the ‘window of opportunity in MS treatment’. Data from a presentation by Dr. Aaron Miller from the USA showed that early treatment with teriflunomide (Aubagio, Genzyme, A Sanofi Company) can lower the likelihood that someone with clinically isolated syndrome (a single, isolated neurological episode) will convert to clinically definitive MS and, in patients who are already relapsing, decrease the risk of new relapses and lesions seen on MRI scans. A number of related trials have confirmed the benefits of early treatment in preventing people with CIS from developing MS.

Silencing the disease from the start

During this morning’s opening lecture, Professor Giancarlo Comi from Italy noted that the extent of tissue damage in the brain in late stage MS depends on the events which take place earlier on. Thus, if treated early, people with MS may experience a much more positive outcome. In addition, treating MS at the early signs of tissue damage can avoid exhaustion of the protective mechanisms used by our brains to recover from such trauma.

It’s quite exciting to hear about the new frontiers in MS treatment, and we look forward to hearing more in this area over next few days.

Until next time!